Top Markets
#1 MarsCoin MarsCoin +55.22%
#2 Palladium Network Palladium Network +52.93%
#3 Siren Siren +27.72%
#4 Useless Coin Useless Coin +25.64%
#5 Status Status +20.53%
#6 edgeX edgeX +18.18%
#7 Bedrock Bedrock +17.35%
#8 PondCoin PondCoin +15.89%
#9 Asteroid Shiba Asteroid Shiba +15.47%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
Coin of the day
MarsCoin MarsCoin
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
KemPharm, Inc. KemPharm, Inc.

KemPharm, Inc.

KMPH
Classificação em ações #18404
KemPharm, Inc. operates as a specialized pharmaceutical firm focused on... KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.
Preço da ação
$5.81
Última sincronização: 2023-02-28
Valor de mercado
$200.14M
Variação (1 dia)
-0.34%
Variação (1 ano)
0.00%
País
US
Negociar KemPharm, Inc. (KMPH)

Categoria

Healthcare
EPS de KemPharm, Inc. (KMPH)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da KemPharm, Inc., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da KemPharm, Inc. de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH